Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Magenta Therapeutics (MGTA) shares

Learn how to easily invest in Magenta Therapeutics shares.

Magenta Therapeutics is a biotechnology business based in the US. Magenta Therapeutics stocks (MGTA.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $11.39 – a decrease of 17.31% over the previous week. Magenta Therapeutics employs 73 staff and has a market cap (total outstanding stock value) of $255.1 million.

How to buy shares in Magenta Therapeutics

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – MGTA – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Is it a good time to buy Magenta Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

How has Coronavirus impacted Magenta Therapeutics's stock price?

Since the stock market crash in March caused by coronavirus, Magenta Therapeutics's stock price has had significant negative movement.

Its last market close was $4.3, which is 69.29% down on its pre-crash value of $14 and 33.95% down on the lowest point reached during the March crash when the stocks fell as low as $5.76.

If you had bought $1,000 worth of Magenta Therapeutics stocks at the start of February 2020, those stocks would have been worth $518.87 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth $361.03.

Magenta Therapeutics stock price (NASDAQ:MGTA)

Use our graph to track the performance of MGTA stocks over time.

Magenta Therapeutics shares at a glance

Information last updated 2022-01-18.
Latest market close$4.30
52-week range$4.38 - $14.20
50-day moving average $5.69
200-day moving average $8.13
Wall St. target price$13.00
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-1.34

Compare online stock trading platforms

Note: The dollar amounts in the table below are in Canadian dollars.

Name Product Finder Rating Stock Trading Fee Account Fee Available Asset Types Offer
Wealthsimple Trade
Finder Rating:
3.9 / 5
Stocks, ETFs
Get 2 free stocks when you deposit and trade $150.
Scotia iTRADE
Finder Rating:
3.8 / 5
$4.99 - $9.99
Bonds, Options, Mutual Funds, ETFs, GICs, International Equities
Interactive Brokers
Finder Rating:
4.1 / 5
Min. $1.00, Max. 0.5%
Stocks, Bonds, Options, ETFs, Currencies, Futures
CIBC Investor's Edge
Finder Rating:
4 / 5
$4.95 - $6.95
$0 if conditions met, otherwise $100/year
Stocks, Bonds, Options, Mutual Funds, ETFs
Get up to $2,000 cash back. Conditions apply. Offer ends March 1, 2022.
Finder Rating:
4.2 / 5
$4.95 - $9.95
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs, International Equities, Precious Metals
Get $50 in free trades when you fund your account with a minimum of $1,000.
Qtrade Direct Investing
Finder Rating:
4.1 / 5
$6.95 - $8.75
$0 if conditions met, otherwise $25/quarter
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs
Get a $50 bonus when you open a new RRSP, TFSA or RESP and start pre-authorized contributions of $200+/month. Valid until March 1, 2022.

Compare up to 4 providers

Online stock trading

Magenta Therapeutics price performance over time

Historical closes compared with the close of $4.3 from 2022-01-18

1 week (2022-01-11) -11.52%
1 month (2021-12-15) N/A
3 months (2021-10-19) -32.60%
6 months (2021-07-19) -50.23%
1 year (2021-01-19) -49.20%
2 years (2020-01-17) -69.55%
3 years (2019-01-18) 7
5 years (2017-01-15) N/A

Magenta Therapeutics financials

Gross profit TTM $0
Return on assets TTM -24.16%
Return on equity TTM -40.21%
Profit margin 0%
Book value $3.26
Market capitalisation $255.1 million

TTM: trailing 12 months

Magenta Therapeutics share dividends

We're not expecting Magenta Therapeutics to pay a dividend over the next 12 months.

Magenta Therapeutics share price volatility

Over the last 12 months, Magenta Therapeutics's shares have ranged in value from as little as $4.38 up to $14.2. A popular way to gauge a stock's volatility is its "beta".

MGTA.US volatility(beta: 1.97)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Magenta Therapeutics's is 1.9663. This would suggest that Magenta Therapeutics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Magenta Therapeutics overview

Magenta Therapeutics, Inc. , a clinical-stage biotechnology company, develops novel medicines to bring the curative power of stem cell transplant, gene therapy, genome editing, and cell therapy to patients. The company is developing C100 and C300 targeted antibody-drug conjugates for transplant conditioning; MGTA-145, a stem cell mobilization product candidate to control stem cell mobilization; MGTA-456, an allogeneic stem cell therapy to control stem cell growth; E478, a small molecule aryl hydrocarbon receptor antagonist for the expansion of gene-modified stem cells; and G100, an antibody-drug conjugate program to prevent prophylaxis of graft-versus-host diseases. It has a has a research and clinical collaboration agreement with AVROBIO, Inc. to evaluate potential utility of MGTA-117 for conditioning of patients receiving one or more investigational lentiviral gene therapies; and clinical trial collaboration with bluebird bio, Inc. to evaluate the utility of MGTA-145, in combination with plerixafor, for mobilization and collection of stem cells in adults and adolescents with sickle cell disease. The company was formerly known as HSCTCo Therapeutics, Inc.

Frequently asked questions

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, CFDs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading CFDs and forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More on investing

More guides on Finder

Go to site